Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) is an American multinational corporation founded in 1886, widely recognized as the world’s largest and most diversified healthcare company. The company is structured into three main segments: pharmaceuticals, medical devices and diagnostics, and consumer health products. The pharmaceutical division, which contributes significantly to the company's revenue, focuses on therapeutic areas such as immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The medical devices segment specializes in orthopedics, surgical instruments, and vision care. The consumer health division, known for products in baby care, beauty, oral care, over-the-counter drugs, and women's health, is set to be divested in 2023 under the new name Kenvue.
In recent developments, Johnson & Johnson has made headlines with the expanded approval of CARVYKTI® (ciltacabtagene autoleucel), a one-time infusion therapy for multiple myeloma. This approval is based on the successful Phase 3 CARTITUDE-4 study, showing a significant reduction in disease progression or death by 59% compared to traditional therapies. Such advancements underscore Johnson & Johnson's dedication to innovative treatments, particularly in oncology.
Financially, Johnson & Johnson generates over half of its revenue from the United States, with the pharmaceuticals and medical devices divisions driving the majority of cash flows. The company continues to invest heavily in research and development, aiming to transform healthcare through smarter and less invasive treatments. Their strategic partnerships and focus on emerging markets further cement their position as a leader in the healthcare industry.
With a commitment to improving global health, Johnson & Johnson's innovative solutions span across the full spectrum of healthcare, striving to prevent, treat, and cure complex diseases. For more information, visit their official website at www.jnj.com.
On September 21, 2021, Johnson & Johnson (NYSE: JNJ) shared new data affirming that its COVID-19 vaccine provides strong and long-lasting protection. A real-world effectiveness study indicated an efficacy rate of 79% for infections and 81% for hospitalizations. Additionally, a booster shot significantly enhanced protection, offering 94% efficacy against symptomatic COVID-19. The booster also heightened antibody levels by up to twelve times. The company has communicated these findings to regulatory agencies, including the FDA and WHO, as part of ongoing efforts to combat the pandemic.
Johnson & Johnson (NYSE: JNJ) will conduct a conference call on October 19, 2021, at 8:30 a.m. ET to review its third-quarter results. Hosted by Joseph J. Wolk, CFO, the call will feature key executives including Ashley McEvoy and Jennifer Taubert. Access the call via www.investor.jnj.com or by phone at 877-869-3847 (U.S.) and 201-689-8261 (international). Replay options will be available until November 2. The press release will be accessible at 6:45 a.m. ET that day.
On September 13, 2021, Johnson & Johnson (NYSE: JNJ) announced promising results for its Ebola vaccine regimen, Zabdeno® and Mvabea®, published in The Lancet Infectious Diseases. The Phase 3 EBOVAC-Salone study showed robust antibody responses in adults and children, persisting for at least two years. Booster doses further enhanced immune responses within a week. Conducted in Sierra Leone, the study demonstrated no safety concerns. The vaccine, granted EU marketing authorization in July 2020, aims to prevent future Ebola outbreaks, highlighting Johnson & Johnson's commitment to global public health.
Johnson & Johnson faces legal challenges as women with ovarian cancer seek a temporary restraining order against the company. They allege that J&J plans to transfer about $24 billion in potential talc-related liabilities to a subsidiary to seek bankruptcy protection, potentially limiting victim compensation. This move may halt ongoing litigation on a national scale. The legal strategy, known as the 'Texas Two-Step,' is seen as a way to evade financial responsibility. Critics argue that this abuse of bankruptcy threatens victims' rights to fair trials.
On August 26, 2021, a California jury awarded $26.5 million to a woman whose mesothelioma was linked to Johnson & Johnson's talcum powder products. This verdict adds to a growing trend of jury findings against J&J concerning the carcinogenic nature of talc. Reports reveal that a significant percentage of talc-based products sold by the company contained asbestos, which J&J allegedly concealed from the public and regulators. The company has indicated intentions to bundle such liabilities into a separate entity and pursue bankruptcy protection, raising concerns about accountability for victims.
Johnson & Johnson (NYSE: JNJ) announced that its Phase 2b Imbokodo HIV vaccine trial did not provide sufficient protection against HIV in young women in sub-Saharan Africa. While the vaccine showed a favorable safety profile, with no serious adverse events, the study will not continue. The trial involved over 2,600 participants, and the primary analysis indicated a vaccine efficacy of 25.2%, which was not statistically significant. Ongoing research from this trial may aid future HIV vaccine development. J&J continues its Phase 3 Mosaico study, testing a different vaccine regimen in men and transgender individuals.
Johnson & Johnson (NYSE: JNJ) will participate in the Cantor Virtual Global Healthcare Conference on September 28, 2021. Mathai Mammen, Global Head of Research & Development at Janssen, and Scott White, Company Group Chairman of NA Pharmaceuticals, will represent the company in a session at 10:00 a.m. ET.
The live webcast can be accessed via the Johnson & Johnson website, with a replay available 48 hours post-event.
Johnson & Johnson (NYSE: JNJ) announced promising data supporting the use of its COVID-19 vaccine as a booster for individuals previously vaccinated with its single-shot vaccine. Interim findings show that a booster dose significantly increases spike-binding antibodies by nine-fold compared to 28 days post-primary vaccination. The company is working with health authorities to discuss potential booster strategies. These results follow earlier Phase 1/2a studies demonstrating strong antibody responses lasting eight months post-vaccination.
Ovarian cancer victims are seeking a court order to prevent Johnson & Johnson (NYSE:JNJ) from moving its $500 billion assets to a subsidiary and declaring bankruptcy. This tactic, referred to as the "Texas Two-Step," aims to shield J&J from over $17 billion in liabilities linked to talc-cancer lawsuits.The plaintiffs argue that this move constitutes fraudulent conveyance, potentially halting over 34,000 claims. A trial in Missouri is scheduled for September 7, raising concerns over the implications for personal injury claimants if J&J's plan proceeds.
On August 19, 2021, Johnson & Johnson (NYSE: JNJ) announced that Alex Gorsky will transition into the role of Executive Chairman while Joaquin Duato, currently Vice Chairman, will become CEO, effective January 3, 2022. Gorsky has led the company as CEO since 2012, overseeing a 60% increase in R&D investments, reaching $12 billion in 2020. He emphasized the company's strong performance across all segments. Duato expressed enthusiasm for leading the company, highlighting its unmatched healthcare platform. The Board acknowledged the effective succession planning that enabled this leadership transition.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
What are the main business segments of Johnson & Johnson?
What recent developments have there been in Johnson & Johnson's pharmaceutical division?
What products are included in Johnson & Johnson’s consumer health segment?
What is CARVYKTI®?
What percentage of Johnson & Johnson's revenue is generated in the United States?
What is the focus of Johnson & Johnson’s medical devices segment?
What changes are happening with Johnson & Johnson’s consumer health division?
How does Johnson & Johnson contribute to global healthcare?
Where can I find more information about Johnson & Johnson?
What therapeutic areas does Johnson & Johnson's pharmaceutical division focus on?
